MedTrace Logo

Masitinib Plus Gemcitabine in Pancreatic Cancer

NCT03766295 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 377

Last updated 2020-12-08

No results posted yet for this study

Summary

The objective is to compare efficacy and safety of masitinib in combination with gemcitabine to placebo in combination with gemcitabine, in treatment of patients with locally advanced or metastatic pancreatic cancer and who have pain related to the disease.

Conditions

  • Locally Advanced or Metastatic Pancreatic Cancer

Interventions

DRUG

Masitinib

DRUG

Gemcitabine

DRUG

Placebo

Sponsors & Collaborators

  • AB Science

    lead INDUSTRY

Principal Investigators

  • Joël Ezenfis, MD · Centre Hospitalier de Longjumeau, France

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2020-12-31
Completion
2020-12-31
FDA Drug
Yes

Countries

  • Belgium
  • France
  • Greece
  • India
  • Russia
  • Slovakia
  • Tunisia
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03766295 on ClinicalTrials.gov